Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | WRN | Q14191 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18025372 | 0.90 | CHRM2 (0.31) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL26049973 | 0.87 | ALDH1A1 (0.35) | KMT2AALDH1A1 | |
| SCHEMBL23743608 | 0.83 | — | — | |
| SCHEMBL24493563 | 0.83 | — | — | |
| SCHEMBL23469904 | 0.83 | KMT2A (0.30) | KMT2A | |
| SCHEMBL15691984 | 0.83 | — | — | |
| SCHEMBL19369854 | 0.82 | ACE (0.35) | TSHR | |
| SCHEMBL21116928 | 0.82 | TSHR (0.41) | KMT2AALDH1A1TSHR | |
| SCHEMBL24770415 | 0.82 | NAAA (0.44) | KMT2A | |
| SCHEMBL19901104 | 0.82 | ACE (0.33) | CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019049-A1 | METHODS FOR PREPARING THERAPEUTIC PROTEIN-POLYMER CONJUGATES | Takeda Pharmaceutical Company Limited (JP) | 2022-06-29 | — | — | EP | disclosed |
| US-11186719-B2 | Hemicyanine dyes | LI-COR, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| EP-2320954-B1 | DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES | BRACCO IMAGING SPA (IT) | 2019-09-04 | — | — | EP | disclosed |
| WO-2018086139-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LIKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2018-05-17 | — | — | WO | disclosed |
| EP-2947111-B1 | MONOFUNCTIONAL BRANCHED POLYETHYLENEGLYCOL AND BIO-RELATED SUBSTANCE MODIFIED BY SAME | XIAMEN SINOPEG BIOTECH CO LTD (CN) | 2018-03-07 | — | — | EP | disclosed |
| US-20170202975-A1 | DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL-BINDING MOLECULE | SUZHOU M-CONJ BIOTECH CO., LTD. (CN) | 2017-07-20 | — | — | US | disclosed |
| WO-2016196994-A9 | REAGENTS FOR QUANTITATIVE MASS SPECTROMETRY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202975-A1 | DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL-BINDING MOLECULE | CD74, CD2, EPCAM | CHRM2 4675/4885CHRM4 4502/4885CHRM1 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.